Nora Tu
Research Subjects
Nora Tu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Charles Dharmani
Daiichi Sankyo, Inc
5 shared publications - Maribel Salas
Bayer Pharmaceuticals, Whippany, USA
4 shared publications - Oluwatosin Fofah
Daiichi Sankyo, Inc
4 shared publications - Eric Wang
Daiichi-Sankyo, Inc., Basking Ridge, NJ 07920, USA
3 shared publications - Aimee Near
IQVIA, Durham, NC, USA
2 shared publications Margaret Wooddell
Daiichi Sankyo, Inc., 211, Mt. Airy Road, Basking Ridge, NJ 07920, USA
2 shared publications
Latest Publications
- Open Access
- 18 May 2025
- Published by Taylor & Francis in Future Cardiology
- Vol. 21 (8) , 593-598
Identifying ventricular arrhythmia and sudden cardiac arrest in clinical notes of an electronic health record database
Validating an operational algorithm for identifying ventricular arrhythmia and sudden cardiac arrest (VA/SCA) in electronic health record (EHR) data may be useful to minimize measurement bias in studies characterizing real-world VA/SCA risk; however, validation studies require an appropriate reference standard. We aimed to assess if adequate information is documented in unstructured clinical notes of a large EHR database to serve as a reference standard for future validation studies of VA/SCA. Twenty potential VA/SCA events were randomly selected from unstructured clinical notes of a large EHR database, TriNetX Dataworks - USA. These notes were reviewed to assess if key clinical elements were documented to confirm the occurrence of VA/SCA and describe their clinical features. These included explicit documentation of an acute event, electrocardiogram (ECG) findings, urgent medical interventions, and other elements. Explicit documentation of an acute event was recorded for 17 patients (85.0%) and ECG findings were documented for 15 patients (75.0%). Generally, unstructured clinical notes also contained information about signs and symptoms, care setting, medical interventions administered, and event resolution. The unstructured clinical notes of a large EHR database contained the information necessary to serve as a reference standard for validation studies of a VA/SCA operational algorithm in EHR data.
- 18 May 2025
- Published by Taylor & Francis in Future Cardiology
- Vol. 21 (8) , 593-598
Open AccessIdentifying ventricular arrhythmia and sudden cardiac arrest in clinical notes of an electronic health record database
Validating an operational algorithm for identifying ventricular arrhythmia and sudden cardiac arrest (VA/SCA) in electronic health record (EHR) data may be useful to minimize measurement bias in studies characterizing real-world VA/SCA risk; however, validation studies require an appropriate reference standard. We aimed to assess if adequate information is documented in unstructured clinical notes of a large EHR database to serve as a reference standard for future validation studies of VA/SCA. Twenty potential VA/SCA events were randomly selected from unstructured clinical notes of a large EHR database, TriNetX Dataworks - USA. These notes were reviewed to assess if key clinical elements were documented to confirm the occurrence of VA/SCA and describe their clinical features. These included explicit documentation of an acute event, electrocardiogram (ECG) findings, urgent medical interventions, and other elements. Explicit documentation of an acute event was recorded for 17 patients (85.0%) and ECG findings were documented for 15 patients (75.0%). Generally, unstructured clinical notes also contained information about signs and symptoms, care setting, medical interventions administered, and event resolution. The unstructured clinical notes of a large EHR database contained the information necessary to serve as a reference standard for validation studies of a VA/SCA operational algorithm in EHR data.
- Open Access
- 21 February 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (16) , 1079-1097
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or f... Plain language summary – Treatment patterns in patients with tenosynovial giant cell tumors in the USA This database study is the first investigation of how drugs are used to treat patients with te...
- 21 February 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (16) , 1079-1097
Open AccessReal-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the only US FDA-approved treatment for TGCT associated with severe morbidity or f... Plain language summary – Treatment patterns in patients with tenosynovial giant cell tumors in the USA This database study is the first investigation of how drugs are used to treat patients with te...
- Open Access
- 10 October 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (15) , 1013-1030
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma
Objective: To evaluate treatment patterns, healthcare resource utilization (HRU) and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. Methods: A retrospective cohort study, using ... Plain language summary – How are patients with peripheral T-cell lymphoma treated in the real world & how much does it cost? Peripheral T-cell lymphomas (PTCL) are a rare and fast-growing form of b... Tweetable abstract Treatment patterns and costs in peripheral T-cell lymphoma.
- 10 October 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (15) , 1013-1030
Open AccessReal-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma
Objective: To evaluate treatment patterns, healthcare resource utilization (HRU) and costs among peripheral T-cell lymphoma (PTCL) patients in the USA. Methods: A retrospective cohort study, using ... Plain language summary – How are patients with peripheral T-cell lymphoma treated in the real world & how much does it cost? Peripheral T-cell lymphomas (PTCL) are a rare and fast-growing form of b... Tweetable abstract Treatment patterns and costs in peripheral T-cell lymphoma.
- Open Access
- 22 June 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (24) , 1677-1693
Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes
Aim: Elderly acute myeloid leukemia (AML) patients are often not treated with antileukemic therapy due to their poor overall health condition, leaving supportive care as the sole treatment option. ... Plain language summary - Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment p...
- 22 June 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (24) , 1677-1693
Open AccessElderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes
Aim: Elderly acute myeloid leukemia (AML) patients are often not treated with antileukemic therapy due to their poor overall health condition, leaving supportive care as the sole treatment option. ... Plain language summary - Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment p...
- Open Access
- 1 January 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (2) , 159-171
Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiologyand End Results-Medicare database
Background: Without treatment, acute myeloid leukemia (AML) is rapidly fatal. Nevertheless, a large proportion of elderly AML patients do not receive any treatment. Aim: To characterize the demogra... Plain language summary An analysis of the data collected in the Surveillance, Epidemiology and End Results-Medicare database from 2008 to 2015 was performed. This database includes data collected b...
- 1 January 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (2) , 159-171
Open AccessCharacteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiologyand End Results-Medicare database
Background: Without treatment, acute myeloid leukemia (AML) is rapidly fatal. Nevertheless, a large proportion of elderly AML patients do not receive any treatment. Aim: To characterize the demogra... Plain language summary An analysis of the data collected in the Surveillance, Epidemiology and End Results-Medicare database from 2008 to 2015 was performed. This database includes data collected b...